Free tool
FAERS Monitor: Kenalog-40
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 014901 or its brand name (Kenalog-40, Triamcinolone Acetonide). Reports on generic versions are filed under their own applications.
Reports
26,375
Serious
13,659
52% of reports
Hospitalization
6,462
Death reported
3,186
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,884
- off label use2,930
- pruritus2,762
- rash2,589
- pain2,199
- fatigue2,074
- nausea1,988
- product use in unapproved indication1,770
- diarrhoea1,720
- vomiting1,716
- headache1,688
- condition aggravated1,682
- arthralgia1,578
- dizziness1,503
- infusion related reaction1,419
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 145 |
| 2005 | 141 |
| 2006 | 181 |
| 2007 | 146 |
| 2008 | 232 |
| 2009 | 191 |
| 2010 | 195 |
| 2011 | 293 |
| 2012 | 206 |
| 2013 | 228 |
| 2014 | 368 |
| 2015 | 600 |
| 2016 | 789 |
| 2017 | 970 |
| 2018 | 1,175 |
| 2019 | 1,313 |
| 2020 | 1,533 |
| 2021 | 1,813 |
| 2022 | 2,342 |
| 2023 | 2,752 |
| 2024 | 3,567 |
| 2025 | 3,888 |
| 2026 | 3,307 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,027,784 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 1,419 | 17.4 | 16.6 | 21,548 |
| pruritusSignal | 2,762 | 5.8 | 5.6 | 10,998 |
| product use in unapproved indicationSignal | 1,770 | 5.7 | 5.5 | 6,937 |
| rashSignal | 2,589 | 4.8 | 4.6 | 7,799 |
| condition aggravatedSignal | 1,682 | 4.4 | 4.2 | 4,505 |
| arthralgiaSignal | 1,578 | 3.0 | 2.9 | 2,185 |
| vomitingSignal | 1,716 | 2.9 | 2.8 | 2,202 |
| painSignal | 2,199 | 2.9 | 2.7 | 2,731 |
| off label useSignal | 2,930 | 2.7 | 2.6 | 3,191 |
| dizzinessSignal | 1,503 | 2.4 | 2.3 | 1,261 |
| drug ineffectiveSignal | 3,884 | 2.4 | 2.3 | 3,217 |
| headacheSignal | 1,688 | 2.2 | 2.1 | 1,066 |
| diarrhoeaSignal | 1,720 | 2.1 | 2.0 | 1,057 |
| fatigueSignal | 2,074 | 2.1 | 2.0 | 1,282 |
| nauseaSignal | 1,988 | 2.0 | 1.9 | 1,038 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.